Yumei Ye

Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen

Yelena Kovtun, Charlene A. Audette, Yumei Ye et al. · Cancer Research · 2006 · 474 citations · Full text

Pharmacy, Oncology, Pharmacology +17

SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

Yumei Ye, Mandeep Bajaj, Hsiu‐Chiung Yang et al. · Cardiovascular Drugs and Therapy · 2017 · 366 citations

Medicine, Pharmacology, Pharmacotherapy +17

Downregulation of microRNA-29 by antisense inhibitors and a PPAR-γ agonist protects against myocardial ischaemia–reperfusion injury

Yumei Ye, Zhaoyong Hu, Yu Lin et al. · Cardiovascular Research · 2010 · 201 citations

Life Sciences, Cardiology, Pharmacology +16

Augmentation of Myocardial Production of 15-Epi-Lipoxin-A ₄ by Pioglitazone and Atorvastatin in the Rat

Yochai Birnbaum, Yumei Ye, Yu Lin et al. · Circulation · 2006 · 169 citations · Full text

Medicine, Cardiology, Pharmacology +14

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA

Yumei Ye, Kyle T. Keyes, Congfang Zhang et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2010 · 151 citations

Medicine, Cardiology, Pharmacology +16